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Abstract
Background: Since Professor Hampton announced the death of clinical freedom in 1983, the increasing influence of 
Evidence-based Medicine and Health Technology Assessment has contributed to augment the feeling that clinicians 
have a secondary role in the therapeutic decision-making process.
Discussion: This article constitutes a reflection on how clinicians may use the results of economic evaluations in their 
daily clinical practice, making decisions about cost-effectiveness on a case by case basis, and addressing both the 
patient's and society's needs. To that end, some illustrating examples are taken from the literature to show there are 
factors with great impact on cost-effectiveness results that can be easily identified and modified by clinicians.
Summary: The evolution of the discipline and the trend towards a tailored therapy suggest that health economics is 
not the end of clinical freedom but the start of it.
Background
Twenty five years ago Professor Hampton announced the
death of clinical freedom [1]. He was then ahead of his
time, when he reflected on the need of taking into
account cost of interventions and evaluation techniques
in the clinician's daily routine. Since Professor Hampton's
paper, the increasing influence of Evidence-based Medi-
cine (EBM) and Health Technology Assessment, has con-
tributed to augment the feeling that clinicians play a
secondary role in the therapeutic decision-making pro-
cess.
In a rather simplistic way, one can distinguish an indi-
vidual-patient ethic of effectiveness, based on providing
each individual patient with the best available alternative,
regardless of cost, and a population-health ethic of effi-
ciency, based on providing the population with the best
option according to available resources [2], but either
way, it seems that treatment decisions increasingly
depend on the results of meta-analyses, systematic
reviews, and economic evaluations conducted by organi-
sations such as the Cochrane Collaboration or NICE, to
give but two very influential examples.
However , it would be a mistake to consider that doc-
tor's new role is limited to automatically applying an evi-
dence-based knowledge, or the results of the economic
evaluations. In a patient-centered health care system it is
just as harmful for clinicians not to take EBM or cost-
effectiveness (CE) into consideration as it is for EBM and
CE not to take doctors into consideration.
In the early days of CE analyses, it was very common to
see generalizations and simplifications about the superi-
ority or inferiority of one specific technology in compari-
son with other alternatives [3]. Fortunately, it is now
increasingly common to see more sophisticated evalua-
tions that try to take into account the full complexity and
nuances of real clinical practice, analysing the different
results in different subgroups of patients. This evolution
to ensure that economic evaluations adapt their conclu-
sions to patient subpopulations can be considered as one
step forward in the "tailored therapy" concept. In general,
health interventions are not efficient or inefficient in
themselves but their efficiency depends on how they are
used in each patient. Doctors are who finally decide how
to use a certain technology in every specific patient. The
efficacy and efficiency are usually obtained through
quantitative methods (i.e. clinical trials and decision ana-
lytic models) that provide the best evidence for the aver-
age patient. But the best decision for the average patient
is not necessarily the best decision for every single
patient.
CE results should be considered as the starting point
for doctors to decide what the "best" alternative in every
case is, after taking into account all the relevant informa-
tion of each individual patient. This article constitutes a
* Correspondence: sacristan_jose@lilly.com
1 Clinical Research Department. Eli Lilly and Company, Avenida de la Industria 
30, Alcobendas, 28108 Madrid, Spain
Full list of author information is available at the end of the articleSacristán et al. BMC Health Services Research 2010, 10:183
http://www.biomedcentral.com/1472-6963/10/183
Page 2 of 3
reflection on how clinicians may use the results of eco-
nomic evaluations of health interventions in their daily
clinical practice, making decisions about cost-effective-
n e s s  o n  a  cas e  b y  case  bas i s,  a n d  a d d r e s s i n g  bo t h  t h e
patient's and society's needs. To that end, some illustrat-
ing examples are taken from the literature.
Discussion
Results of cost-effectiveness analysis can be influenced by
many factors. Some of them, such as the time horizon of
the analysis or perspective of the analysis, are inherent to
the characteristics of health economic models. However,
others factors, such as the subgroup of patients for whom
the intervention is most beneficial, the potential alterna-
tive treatments, or the best way to measure the outcome
of a particular intervention, can be easily identified by cli-
nicians.
The importance of subgroup analyses can be illustrated
with the example of a CE study of cholesterol-lowering
therapies analysed according to selected patient charac-
teristics [4]. In the study women and men aged 35 to 84
years with high low-density lipoprotein cholesterol
(LDLC) levels were divided into different risk subgroups
according to age, sex, and the presence or absence of four
coronary heart disease risk factors (smoking status, blood
pressure, LDLC level, and high-density lipoprotein cho-
lesterol level) for the economic evaluation. The results
showed that incremental cost-effectiveness ratios (ICERs)
for primary prevention with a statin compared with
dietary management ranged from $54,000 per QALY to
$1,400,000 per QALY, depending on risk subgroup char-
acteristics. So, there are subpopulations for whom this
intervention is not cost-effective because their corre-
sponding CE ratios far exceed any international thresh-
old, but it is also possible to identify the optimal
subpopulation for whom the treatment meets the bench-
mark adopted by decision-makers. Identifying these
patient subgroups for whom the technology might be
particularly clinically and cost-effective, is a clear
achievement in the economic evaluation but it must be
translated into a more individualized therapy at the doc-
tor's office. In this context, clinicians play a decisive role
targeting the patient subgroups that will most benefit
from a particular intervention, thus achieving a more effi-
cient use.
The results of an economic evaluation of a health inter-
vention may also vary depending on the choice of com-
parator [5]. An economic analysis performed on
pegabtanib (indicated for age-related macular degenera-
tion) showed how ICERs varied according to the compar-
ator selected [6]. The incremental cost per QALY in
patients receiving pegaptanib compared with those
receiving photodynamic therapy with verteporfin was
$49,052 and $59,039 for patients receiving pegaptanib
v e r s u s  s t a n d a r d  o f  c a r e .  I f  a  d e c i s i o n  w a s  t o  b e  m a d e
based strictly on US efficiency limits (i.e. $50,000), pegap-
tanib would only be considered a cost-effective option vs.
photodynamic therapy with verteporfin. For this reason,
when doctors are considering using a particular thera-
peutic intervention, they must think carefully about the
alternative treatment for that same patient, since this
information will influence treatment efficiency.
With regard to the outcome measures, efficacy usually
differs from effectiveness. Factors such as adherence rate,
dose adjustment, length of treatment, use of concomitant
medication etc. may explain the difference. The CE analy-
sis of angiotensin-converting-enzyme inhibitor therapy
for diabetic nephropathy confirms the importance of
treatment adherence in clinical practice, since ICERs var-
ied substantially with different adherence rates [7].
Changes in the compliance rate from 65% to 51% could
result in a swing in CE from $4,091 per QALY to
$1,176,738 per QALY. Clinicians play a very active role in
improving patients' adherence to treatment, contributing
to closing the gap between efficacy and effectiveness and
consequently improving patients' outcomes and the cost-
effectiveness of interventions. Doctors could also con-
tribute towards more efficient medicine by prescribing
formulations that facilitate therapeutic compliance only
in patients who have shown poor treatment adherence.
In addition, the decision-making process is not based
solely on efficiency criteria since social values judgments
are applied to enhance fairness and reduce health
inequalities. Although the growing importance of these
social value judgements may be acknowledged, we must
not neglect "individual patient values". Accounting for
patient preferences and quality-of-life concerns may shift
the balance of CEA results of particular health interven-
tions. For example, incorporating patient-derived prefer-
ences regarding complications and treatments of diabetes
improved ICERs for intensive glucose control in older
type 2 diabetic patients [8]. However, in daily practice, it
is doctors who may incorporate these factors in their clin-
ical decisions. Doctors make therapeutic decisions based
on the available information for average patients, but they
are aware that, sometimes, individual patient values may
modify these decisions. For example, patients may refuse
a cancer treatment that is backed by clinical trial evidence
and has positive cost-effectiveness, simply because they
are reluctant to suffer the side effects of the therapy, or
they may prefer avoiding an inconvenient preventive
intervention because they are willing to take the bigger
risk of getting the disease, or suffering the complication
that the intervention sought to prevent. Just as the scien-
tific value judgements of organisations such as NICE
should be "individualized" for each patient by the doctor,
social value judgements should be put within the per-
spective of individual value judgements.Sacristán et al. BMC Health Services Research 2010, 10:183
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Some ethical challenges may arise from the clinical
implementation of these reflections, in relation to the
principle of distributive justice: is the practice of patient-
centered care compatible with a fair and equal allocation
of health care resources? [9]. Ensuring a better use of
available health care resources by targeting therapies to
the patients' subgroups that can benefit most leads to
improvements in its cost-effectiveness at individual level
and this shouldn't cause ethical concerns, but quite the
opposite.
In conclusion, in the era of individualized medicine,
decisions about CE should also be made on a case by case
basis. Experts in methodology and decision makers
should focus on evaluating interventions, whereas clini-
cians are the professionals who evaluate patients. Society
must establish social value judgments if resources are to
be distributed with efficiency and equity, but only doctors
can take individual value judgments into account, and
these values must have special relevance in the times of
evidence-based medicine and efficient medicine. In these
times, physicians must be aware of their crucial role
choosing the best intervention for every patient, consid-
ering that the efficacy and efficiency are abstract con-
cepts that become real only when the intervention is used
in the individual patient in the daily clinical practice. For
all the reasons highlighted above, we believe health eco-
nomics shouldn't be considered the end of clinical free-
dom, but the start of it.
Summary
• The evolution of the discipline of economic evaluation
in health care shows that clinicians must play a decisive
role if we are to achieve the target of having a more effi-
cient health service.
• Interventions are not efficient or inefficient per se,
their efficiency is determined when they are used in clini-
cal practice.
• Even if the practice of personalized medicine may
seem challenged by ethical issues, social and individual
value judgments are not mutually exclusive.
• Health economics is not the end of clinical freedom
but the start of it. Doctors take up a central position in
the health care system and they may contribute to finding
the right balance between clinical freedom and social
responsibility.
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